SCHEMBL15545765

SCHEMBL15545765

CCON=C(c1ccc(OC)cc1)c1cc(CC(=O)O)c(-c2ccc(Cl)cc2)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
RXFP1 Q9HBX9 2/20 0.61
PTGDR2 Q9Y5Y4 4/20 0.44
AKR1C4 P17516 2/20 0.42
PTGS1 P23219 2/20 0.42
AKR1C3 P42330 2/20 0.42
AKR1C2 P52895 2/20 0.42
MAPT P10636 3/20 0.39
HPGD P15428 1/20 0.39
PPARD Q03181 1/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
OPRD1 P41143 1/20 0.38
TP53 P04637 1/20 0.38
PSEN1 P49768 3/20 0.37
PSEN2 P49810 3/20 0.37
APH1B Q8WW43 3/20 0.37
NCSTN Q92542 3/20 0.37
APH1A Q96BI3 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19413876 1.00 MEN1 (0.61) MEN1KMT2ARXFP1PTGDR2AKR1C4
SCHEMBL18035681 1.00 MEN1 (0.61) MEN1KMT2ARXFP1PTGDR2AKR1C4
SCHEMBL15546807 0.92 MEN1 (0.63) MEN1KMT2ARXFP1PTGDR2AKR1C4
SCHEMBL19413881 0.90 KMT2A (0.49) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL16893461 0.90 KMT2A (0.49) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL19413844 0.89 MEN1 (0.64) MEN1KMT2ARXFP1PTGDR2AKR1C4
SCHEMBL15545700 0.89 RXFP1 (0.64) MEN1KMT2ARXFP1PTGDR2AKR1C4
SCHEMBL16893444 0.87 RXFP1 (0.49) MEN1KMT2ARXFP1PTGDR2AKR1C4
SCHEMBL16893389 0.85 MEN1 (0.49) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL15545878 0.84 RXFP1 (0.75) MEN1KMT2ARXFP1PTGDR2AKR1C4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US claimed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP claimed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US claimed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP claimed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO claimed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP disclosed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES SLC5A2, SLC5A1, TPMT MEN1 4184/4885KMT2A 4602/4885RXFP1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.